Loading your workspacePreparing the page and its market data.
Polymarket · Tech & ScienceClosed
Loading the chart…
| Outcome | Chance | 24h | 1 week | Bid · Ask | 24h volume | Ends |
|---|---|---|---|---|---|---|
| Yes | 100% | +14 pts | — | >99¢ · 100¢ (<1¢) | — | ended |
No trades of $1,000 or more lately.
This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Gilead Sciences’ new biologics license application (BLA) for lenacapavir as a treatment for Human Immunodeficiency Virus (HIV) by June 19, 2025, 11:59 PM ET. Otherwise, this market will resolve to "No." This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA, however a consensus of credible reporting may also be used.
Sources: Polymarket's Gamma API, its CLOB price history and its Data API, read every two minutes. Prices are each outcome's Yes price, which is the market's probability: 100¢ for Yes means the market gives it about 100%.